EyeBio
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
Overview
Developing next-generation retinal disease therapies through biologics and small molecules.
Ophthalmology
Technology Platform
Integrated platform for developing biologics and small molecules targeting key pathways in retinal disease, including complement and angiogenesis.
Funding History
1Total raised:$65M
Venture$65M
Opportunities
Large and growing aging population driving increased prevalence of retinal degenerative diseases.
Risk Factors
Clinical trial failure risk in a competitive landscape with high regulatory hurdles.
Competitive Landscape
Competes in the crowded but lucrative retinal disease market against established biologics and newer complement inhibitors.